Clinical Analysis and Literature Review of 26 Patients with Hematological Malignancies During Pregnancy.

IF 1.8 Q3 OBSTETRICS & GYNECOLOGY

Women's health reports (New Rochelle, N.Y.) Pub Date : 2025-02-03 eCollection Date: 2025-01-01 DOI:10.1089/whr.2024.0164

Jie Ma, Huimin Zhu, Ling Li, Hui Ma, Bo Zheng

{"title":"Clinical Analysis and Literature Review of 26 Patients with Hematological Malignancies During Pregnancy.","authors":"Jie Ma, Huimin Zhu, Ling Li, Hui Ma, Bo Zheng","doi":"10.1089/whr.2024.0164","DOIUrl":null,"url":null,"abstract":"Background: The hematological malignancies during pregnancy are rare and lethal.Objective: The aim of this study is to demonstrate the incidence, clinical characteristics, treatment, and outcome of hematological malignancies diagnosed during pregnancy.Methods: This is a retrospective study of women who were diagnosed with hematological malignancies during pregnancy at an academic hospital between 2001 and 2021.Results: The incidence rate of 26 pregnant women with hematological malignancies in the pregnant patients admitted to the hospital was about 0.07%. Except for one patient who was diagnosed before pregnancy, the incidence rates of the first, second, and third trimesters of pregnancy were 12% (3/25), 48% (12/25), and 40% (10/25), respectively. Eleven out 26 patients (42.3%) finally gave birth to fetuses. In a long-term follow-up, the survival time of patients with leukemia in pregnancy was shorter than lymphoma (p < 0.05).Conclusion: This report provides a comprehensive description of maternal and infant outcomes and insights into the management of hematological malignancies during pregnancy.","PeriodicalId":75329,"journal":{"name":"Women's health reports (New Rochelle, N.Y.)","volume":"6 1","pages":"147-154"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270522/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Women's health reports (New Rochelle, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/whr.2024.0164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The hematological malignancies during pregnancy are rare and lethal.

Objective: The aim of this study is to demonstrate the incidence, clinical characteristics, treatment, and outcome of hematological malignancies diagnosed during pregnancy.

Methods: This is a retrospective study of women who were diagnosed with hematological malignancies during pregnancy at an academic hospital between 2001 and 2021.

Results: The incidence rate of 26 pregnant women with hematological malignancies in the pregnant patients admitted to the hospital was about 0.07%. Except for one patient who was diagnosed before pregnancy, the incidence rates of the first, second, and third trimesters of pregnancy were 12% (3/25), 48% (12/25), and 40% (10/25), respectively. Eleven out 26 patients (42.3%) finally gave birth to fetuses. In a long-term follow-up, the survival time of patients with leukemia in pregnancy was shorter than lymphoma (p < 0.05).

Conclusion: This report provides a comprehensive description of maternal and infant outcomes and insights into the management of hematological malignancies during pregnancy.

查看原文本刊更多论文

妊娠期血液系统恶性肿瘤26例临床分析及文献复习。

背景：妊娠期血液系统恶性肿瘤罕见且致命。目的：本研究的目的是证明发生率，临床特点，治疗和预后的血液恶性肿瘤诊断在怀孕期间。方法：这是一项回顾性研究，研究对象是2001年至2021年间在一家学术医院诊断为妊娠期血液系统恶性肿瘤的妇女。结果：26例孕妇合并血液系统恶性肿瘤的发生率约为0.07%。除1例在妊娠前确诊外，妊娠前、中、晚期的发病率分别为12%（3/25）、48%（12/25）、40%（10/25）。26例患者中有11例（42.3%）最终分娩。在长期随访中，妊娠期白血病患者的生存时间短于淋巴瘤患者（p < 0.05）。结论：本报告提供了母婴结局的全面描述，并深入了解了妊娠期间血液系统恶性肿瘤的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊